China SXT Pharmaceuticals announces 1-for-150 share consolidation

China SXT Pharmaceuticals Inc. (NASDAQ: SXTC) announced a share consolidation that will combine every 150 ordinary shares into one share, effective February 3, 2026.

The pharmaceutical company said its Class A ordinary shares will begin trading on a post-consolidation basis when markets open on February 3. The shares will continue trading on Nasdaq under the symbol "SXTC" with a new CUSIP number G2161P165.

Before the consolidation, 143,693,892 Class A ordinary shares were issued and outstanding. Following the 1-for-150 consolidation, approximately 957,960 Class A ordinary shares will be outstanding. Fractional shares will be rounded up to the next whole share.

All outstanding stock options, warrants and other rights to purchase the company's Class A ordinary shares will be adjusted proportionately due to the share consolidation. The company is authorized to issue an unlimited number of shares across two classes of ordinary shares with no par value.

Shareholders holding shares through banks, brokers or other nominees will have their shares automatically adjusted to reflect the consolidation. The company's transfer agent is Transhare Corporation.

China SXT Pharmaceuticals focuses on research, development, manufacturing, marketing and sales of Traditional Chinese Medicine Pieces, including various categories of processed traditional Chinese medicine products ready for use.

You May Also Be Interested In

• Bessent: U.S. will enforce 'zero leakage' approach to Iran sanctions
• Tenon Medical back in Nasdaq compliance after reverse stock split
• US Eyes 7.5% China Overcapacity Tariffs Before Xi-Trump Talks - Bloomberg